Most people who stop GLP-1 drugs like Ozempic eventually return
A study presented at the Endocrine Society's annual meeting found that many patients with type 2 diabetes frequently stop and restart GLP-1 medications like Ozempic. The data suggests that treatment patterns are more cyclical than previously assumed, with a majority of patients reinitiating therapy within two years.
Why it matters
It provides new insights into patient adherence for popular diabetes and weight-loss medications.
People taking GLP-1 medications for type 2 diabetes (liraglutide, semaglutide, or tirzepatide) may be more likely to stop and later restart treatment than many people realize, according to research presented Sunday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.
The article is a straightforward summary of medical research findings.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in